Overview of new approaches that aim to improve outcomes for patients with chronic lymphocytic leukemia (CLL) presented at the ESH 3^rd Translational Research Conference: Chronic Lymphocytic Leukaemia.

The BeiGene Satellite Symposium at the XIII^th International Workshop of the German CLL Study Group 2022 was chaired by Prof Barbara Eichhorst and joined by Prof Jennifer Brown. They discussed the current approaches and future direction of targeted therapy with BTK inhibitors for CLL patients.

The Satellite Symposium at EHA2022 was chaired by Paolo Ghia joined by Federico Pea, Barbara Eichhorst, Shirley D’Sa and Ramón García Sanz. They discussed next-generation BTK inhibitors in the treatment of B-cell malignancies.

A video about the mode of action (MoA) of PD-1 inhibitors.

Professor Tam discusses some common chronic lymphocytic leukemia (CLL) disease characteristics and expected treatment outcomes. He introduces the role of Bruton's tyrosine kinase inhibition (BTKi) in CLL, challenges in their use, and hopes for the future treatment of CLL.